Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer Treatment (ROSE)

Noninterventional, Multicentre, Prospective, Cohort Study Assessing the Quality of Life and Hormonal Levels in Premenopausal Patients With Hormone Receptor-positive and HER2-negative Early Breast Cancer in Italy - ROSE Study

The main purpose of this study is to evaluate the quality of life of premenopausal participants with Hormone Receptor (HR) positive and Human Epidermal Growth Factor Receptor-2 (HER2) negative breast cancer who are receiving, in addition to triptorelin, an endocrine cancer treatment. The study will also get more information about: - the effectiveness and safety of triptorelin; - the relationship that could exist between the characteristics of the disease and the treatment chosen by the Investigator.

Study Overview

• Status: Active, not recruiting
• Conditions: Early-stage Breast Cancer

• Study Type: Observational
• Enrollment (Actual): 450

Contacts and Locations

Study Locations

• Italy
  • Bologna, Italy, 40138
    • Policlinico S. Orsola - Malpighi
  • Cagliari, Italy, 9121
    • Ospedale Oncologico "A. Businco"
  • Florence, Italy, 50134
    • Azienda Ospedaliero-Universitaria Careggi (AOUC)
  • Lecco, Italy, 23900
    • ASST Lecco
  • Milan, Italy, 20133
    • Istituto Nazionale Tumori
  • Milan, Italy, 20132
    • IRCCS San Raffaele
  • Milan, Italy
    • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
  • Milan, Italy, 20132
    • Istituto Europeo di Oncologia
  • Monza, Italy
    • Ospedale S. Gerardo
  • Naples, Italy, 80131
    • Istituto Nazionale Tumori - Fondazione Pascale
  • Naples, Italy, 80131
    • AORN Cardarelli
  • Naples, Italy, 80138
    • Università della Campania "L. Vanvitelli"
  • Naples, Italy, 80147
    • P.O. Ospedale del Mare
  • Potenza, Italy, 85100
    • Ospedale San Carlo
  • Pozzuoli, Italy, 80078
    • Ospedale Santa Maria delle Grazie
  • Roma, Italy, 168
    • Policlinico Universitario A. Gemelli (Site A)
  • Roma, Italy, 168
    • Policlinico Universitario A. Gemelli (Site B)
  • Rozzano, Italy
    • Humanitas Cancer Center
  • Torino, Italy
    • Ospedale G. Battista - Molinette
  • Treviglio, Italy, 24047
    • ASST BG OVEST Ospedale di Treviglio
  • Viagrande, Italy, 95029
    • Istituto Oncologico del Mediterraneo (IOM)
  • Vicenza, Italy, 36100
    • Ospedale "S. Bortolo"

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

The study is aimed at premenopausal participants diagnosed with HR-positive and HER2 negative early breast cancer who are starting treatment with triptorelin at the discretion of the treating physician and who consent to participate in the study.

Description

Inclusion Criteria :

• Premenopausal (as per local definition) female patients aged ≥18 years on the day the informed consent is signed;
• Patients have histologically proven, HR-positive and HER2 negative breast cancer according to local definition, determined by immunohistochemistry, and up to stage IIIA. Note: patients with synchronous bilateral breast cancer and patients with breast cancer (BRCA)1/2 gene mutations are eligible;
• Patients have been prescribed adjuvant endocrine treatment with TAM or an AI plus triptorelin (either the 1 month or 3 month formulation) by their treating physician or, in alternative, triptorelin given in combination or consequent to neoadjuvant/adjuvant chemotherapy. Note: the decision to prescribe triptorelin is made by the treating physician prior to and independently of the decision to enroll the patient in this study;
• Patients must be documented to be disease-free at enrolment, as determined by the treating physician according to institutional standards. Note: in case the patient has been prescribed neoadjuvant treatment, the patient will receive surgery and be enrolled but will only remain in the study if disease-free condition is confirmed after surgery. If this condition is not confirmed, then the patient will be discontinued from the study;
• Written informed consent for trial participation must be signed and dated by the patient and the Investigator prior to enrolment;
• Patients have been informed of and agree to data transfer and handling, in accordance with national data protection guidelines;
• Patients must be accessible for follow-up;
• Patients may have received previous treatment with triptorelin for another indication, but the last administration must have occurred at least 6 months before enrolment.

Exclusion Criteria :

• Patient is currently enrolled in any other clinical study or has participated in one within the 12 weeks prior to the Inclusion visit, or is scheduled to receive a new investigational drug while this study is ongoing;
• Patient is not eligible for triptorelin treatment as guided by the product's label in Italy due to safety concerns or has prior history of no responsiveness to triptorelin (in case of previous triptorelin treatment);
• Patient has premenopausal status that cannot be defined;
• Patient has had bilateral oophorectomy or ovarian irradiation;
• Patient has current loco-regional relapse and/or distant metastatic disease;
• Patient has a history of prior (ipsi- and/or contralateral) invasive breast cancer;
• Patient has a history of malignancy other than invasive breast cancer, with the following exceptions: (a) Patients diagnosed, treated and disease-free for at least 5 years and deemed by the Investigator to be at low risk for recurrence of that malignancy are eligible; (b) Patients with the following malignancies are eligible, even if diagnosed and treated within the past 5 years: in situ breast ductal carcinoma; in situ cervical cancer; in situ thyroid cancer; nonmetastatic, no melanomatous skin cancers;
• Patient has concurrent disease or condition that would make study participation inappropriate or any serious medical disorder that would interfere with the patient's safety;
• Patient has psychiatric, addictive, or any other disorder that would prevent compliance with protocol requirements

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of participants reaching a clinically significant change in the global Quality of Life (QoL) score.	Defined as a minimum change of ≥4 points using the Functional Assessment of Cancer Therapy - General (FACT-G) questionnaire.	At 18 months.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Tumor characteristics.		At baseline.
Percentage of days covered of compliance		At 18 months
Description of breast cancer treatment.	Including triptorelin formulation (1-month or 3-month formulation), planned neoadjuvant/adjuvant chemotherapy (yes/no) and oral adjuvant endocrine treatment prescribed ((Aromatase Inhibitor (AI) or Tamoxifen (TAM))	At baseline.
Identification of potential demographic factors predictive of any treatment switch.	A multivariate logistic regression will be used to identify demographic factors predictive of any treatment switches.	At 18 months.
Identification of demographic and tumor characteristics correlated to the entire prescribed breast cancer treatment.	A multivariate logistic regression will be used to identify characteristics correlated to the prescription of the 1-month or 3-month triptorelin formulations with TAM or an AI.	At 18 months.
Proportion of participants who switch between triptorelin formulations, from AI to TAM or vice-versa, or undergo both triptorelin and adjuvant therapy switches	The switches between triptorelin formulation or from the AI to TAM will be described together with the reasons for switches.	At 18 months.
Proportion of disease-free participants.	Disease-free survival is defined as the time from triptorelin initiation to disease recurrence as determined by the Investigator.	At 18 months.
Proportion of participants alive.	The OS rate will be estimated using the Kaplan-Meier method. Survival time will be defined as the time from triptorelin initiation to participant's death for any reason.	At 18 months.
Proportion of compliant patients (100% of the planned injections) to triptorelin		At 18 months.
Identification of potential demographic, tumor-related or breast cancer treatment-related factors predictive of suboptimal OFS.	as per local definition, or empirically defined as E2 levels ranging between 30 and 70 pg/ml according to the average range collected in Italian centers. A multivariate logistic regression will be used to identify predictive factors of suboptimal OFS as per local definition	At 18 months.
Identification of potential demographic, tumor-related or breast cancer treatment-related factors predictive of clinically significant global QoL change	A multivariate logistic regression will be used to identify any predictive factors of clinically significant global QoL change (i.e. ≥4 points).	At 6, 12 and 18 months.
Incidence of all treatment-emergent adverse events (TEAEs)	Summary incidence tables of nonserious and serious AEs, as well as special situations presented overall, by System Organ Class and Preferred term (MedDRA coding) and according to intensity and causality	From baseline up to 18 months.
Change in the Quality of Life (QoL) score using the FACT-G questionnaire with the Endocrine Symptoms (ES) subscale.	All global scores and subscores of the QoL questionnaire will be described at each timepoint. Comparisons will be performed using the paired Student t-test.	From baseline and at 6, 12 and 18 months
Description of demographic data.	Including age at diagnosis, parity, pregnancy desire (yes/no), oocyte cryopreservation (yes/no) and embryo cryopreservation (yes/no);	At baseline.
Description of demographic data	Including Body Mass Index calculation	At baseline.
Proportion of participants with hormonal levels (E1, E2 and FSH) corresponding to Ovarian Function Suppression (OFS)	As per local definition, or empirically defined as E2 levels <30 pg/ml according to the average level collected in Italian centers)	From baseline up to 18 months.

Collaborators and Investigators

• Sponsor: Ipsen
• Investigators: Study Director: Ipsen Medical, Director, Ipsen

Study record dates

Study Major Dates

• Study Start (Actual): June 9, 2022
• Primary Completion (Estimated): June 5, 2026
• Study Completion (Estimated): June 5, 2026

Study Registration Dates

• First Submitted: April 29, 2022
• First Submitted That Met QC Criteria: May 16, 2022
• First Posted (Actual): May 17, 2022

Study Record Updates

• Last Update Posted (Actual): June 1, 2026
• Last Update Submitted That Met QC Criteria: May 29, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Skin Diseases; Breast Diseases; Skin and Connective Tissue Diseases; Breast Neoplasms
• Other Study ID Numbers: CLIN-52014-452

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES

IPD Plan Description

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.

Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

Any requests should be submitted to www.vivli.org for assessment by an independent scientific review board.

• IPD Sharing Time Frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.
• IPD Sharing Access Criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No